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Purpose: Angiogenesis, or new blood vessel formation from existing one, plays both beneficial and detrimental
roles in living organisms in different aspects. Vascular endothelial growth factor (VEGF), a signal protein, well
established as key regulator of vasculogenesis and angiogenesis. VEGF ensures oxygen supply to the tissues when
blood supply is not adequate, or tissue environment is in hypoxic condition. Limited expression of VEGF is necessary,
but if it is over expressed, then it can lead to serious disease like cancer. Cancers that have ability to express VEGF are
more efficient to grow and metastasize because solid cancers cannot grow larger than a limited size without adequate
blood and oxygen supply. Anti-VEGF drugs are already available in the market to control angiogenesis, but they are
often associated with severe side-effects like fetal bleeding and proteinuria in the large number of patients. To avoid
such side-effects, new insight is required to find potential compounds as anti-VEGF from natural sources. In the present
investigation, molecular docking studies were carried out to find the potentiality of Withaferin A, a key metabolite of
Withania somnifera, as an inhibitor of VEGF.
Methods: Molecular Docking studies were performed in DockingServer and SwissDock. Bevacizumab, a commercial
anti-VEGF drug, was used as reference to compare the activity of Withaferin A. X-ray crystallographic structure of VEGF,
was retrieved from Protein Data Bank (PDB), and used as drug target protein. Structure of Withaferin A and Bevacizumab
was obtained from PubChem and ZINC databases. Molecular visualization was performed using UCSF Chimera.
Results: Withaferin A showed favorable binding with VEGF with low binding energy in comparison to Bevacizumab.
Molecular Docking studies also revealed potential protein-ligand interactions for both Withaferin A and Bevacizumab.
Conclusions: Conclusively our results strongly suggest that Withaferin A is a potent anti-VEGF agent as ascertained by
its potential interaction with VEGF. This scientific hypothesis might provide a better insight to control angiogenesis as
well as to control solid cancer growth and metastasis.
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Angiogenesis is a complex process, where angiogenic
endothelial cells undergo a complex process that in-
cludes the secretion of metallo-proteases, cell migration,
endothelial cell division, and proliferation, including the
new blood vessel formation from the endothelium of a
pre-existing vasculature (Bruick and McKnight 2001;* Correspondence: sanjibsaha1991@yahoo.com
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pathogenesis of various disorders like age-related macu-
lar degeneration, proliferative retinopathies, psoriasis,
rheumatoid arthritis, and also most the common fatal
disorder, solid cancer (Ruggeri et al. 2003; Folkman
1995; Ferrara 2001; Garner 1994). Angiogenesis can be
controlled through different anti-angiogenic and pro-
angiogenic factors (Drevs et al. 2004; Petrova et al.
1999). Controlling angiogenesis, we can ensure limited
growth of solid cancer, because cancer cell will starve
without extra supply of nutrients and oxygen (Folkman
1995; Ferrara 2002, 2004).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
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ered as one of the most vital pro-angiogenic factors in-
volved in tumor angiogenesis (Ferrara 2001; Drevs et al.
2004; Ferrara et al. 2003). VEGF family comprising of
glycoproteins designated as VEGF-A, VEGF-B,VEGF-C,
VEGF-D, VEGF-E, placental growth factor (PGF), and
VEGF-F are involved in the regulation of angiogenesis
(Ball et al. 2007; Lee et al. 2010; Otrock et al. 2007;
Fayette and Soria 2005).
The endothelial cells are considered to be a novel tar-
get for the therapies against cancer cells because of their
genomic instability (Frumovitz and Sood 2007; Sood
et al. 2011). VEGF is secreted from stabilized over
expressed tumor cells, and binds to the receptors on the
endothelial cells of existing blood vessels, ultimately
leads to new blood vessels formation from existing one,
which ensures extra nutrient and blood supply for tumor
cell survival, proliferation, and metastasis (Terman and
Stoletov 2001). To control angiogenesis, anti-VEGF
agents and other VEGF inhibitors are being prescribed
in combination with chemotherapy all over the world
(Ferrara et al. 2005; Bender and Yamashiro 2011;
Morabito and Maio 2006; Carter 2000). The anti-VEGF
monoclonal antibody, Bevacizumab, is usually prescribed
for the treatment of malignant cell (Ferrara et al. 2005;
Bossung and Harbeck 2010). Bevacizumab is used not
only in angiogenesis but also in the treatment of breast,
colorectal, and prostate cancer (Ferrara et al. 2005; Boige
and Malka 2005; Kluetz et al. 2010). But Bevacizumab
therapy is associated with serious life threatening side-
effects like proteinuria and fetal bleeding, at least in 38%
patients (Frumovitz and Sood 2007).
Thus, natural bioactive compounds can be a better
way to find new potential anti-VEGF agents with less
side-effect to control angiogenesis. In this perspective, in
the present in silico pharmacological investigation,
Withania somnifera’s key metabolite Withaferin A, was
studied for their inhibitory activity on VEGF. Different
parameters like FullFitness, Gibbs free energy (ΔG), free
energy of binding, inhibition constant (Ki), total energy
of Van der Waals (vdW) force + hydrogen bond (Hbond)
+desolv energy (EVHD), electrostatic energy, total intermo-
lecular energy, frequency of binding, interact surface area.
Ligand bond, non-ligand bond, hydrogen bond, and its
length were studied. A complete interaction profile
(hydrogen bonds, polar, hydrophobic, pi-pi, cation-pi and




The crystal structure (1.7 Å resolution) of the VEGF in
complex with domain 2 of the Flt-1 receptor [PDB:
1FLT], was obtained from the Protein Data Bank (PDB)(Berman et al. 2000). Before Molecular Docking, the
protein crystal structure was cleaned by removing the
water molecules and hetero atoms. Missing residues
(V: 1–12, W: 1–11, X: 1–131, and Y: 1–131) were
supplemented to repair the crystal structure. Figure 1
shows the structure of VEGF. The ligand molecules
Withaferin A [PubChem: 26759748, ZINC: 08234189]
and Bevacizumab [PubChem: 24801581] were re-
trieved from NCBI-PubChem Compound and ZINC da-
tabases (Bolton et al. 2008; Irwin et al. 2012). Figure 2
shows the basic skeleton of Withanolides along with the
structure of Withaferin A, and also the structure of
Bevacizumab. The Merck molecular force field 94
(MMFF94) was utilized for energy minimization of li-
gands, and the charge calculation method was Gasteiger.
MMFF94 was selected because it is applicable to proteins
and other systems of biological significance as well as
achieves MM3-like accuracy for small molecules (Halgren
1996a). Moreover, the point of view of the development of
MMFF94 guided its intended use in pharmaceutical appli-
cations (Halgren 1996a). MMFF94 was developed through
ab initio techniques of quantum-mechanics at its core and
verified by experimental data sets (Halgren 1996a, 1996b,
1996c, 1996d). Halgren, pioneered a novel way to more
accurately model van der Waals interactions in the devel-
opment of MMFF94 (Halgren 1996a, 1996b, 1996c). The
parameterization and performance of MMFF94 for inter-
molecular interactions has already been validated and it
showed parallel performance as OPLS (Optimized Poten-
tials for Liquid Simulations) (Halgren 1996b).
Molecular docking using DockingServer
Molecular Docking calculations were undertaken using
DockingServer (www.dockingserver.com) (Bikadi and
Hazai 2009). DockingServer is a web-based interface to
handle all aspects of molecular docking using AutoDock
tools. It can be used for molecular docking and as well
as for analysis of results. Moreover, protein and ligand
structure can be inputted directly from databases. It has
integrated some chemistry software to calculate different
parameters of docking study in more efficient way. It
was selected because it permits robust molecular
docking in more user friendly way with high efficiency.
The MMFF94 force field (Halgren 1996a) was used for
the energy minimization of ligand molecules (Withaferin
A and Bevacizumab) using DockingServer. Gasteiger
charge calculation method was utilized and partial
charges were added to the ligand atoms. Non-polar
hydrogen atoms were merged, and as well as rotatable
bonds were defined.
Molecular Docking calculations were carried out on
Withaferin A/ Bevacizumab-VEGF protein model. Ne-
cessary hydrogen atoms and solvation parameters were
added to the structure with the help of AutoDock tools
Figure 1 Structural presentation of VEGF (PDB: 1FLT). (A) Biological assembly of VEGF, (B) Surface structure of VEGF, (C) Mesh structure of
VEGF, and (D) Ribbon structure of VEGF.
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(x, y, and z) grid points, and 0.375 Å spacing were auto-
matically generated using the AutoGrid program (Morris
et al. 1998). Box center was x: 0.38 Å, y: -2.98 Å and z:
20.51 Å.
Parameter set- and distance-dependent dielectric func-
tions of AutoDock were used for calculating van der
Waals and the electrostatic forces, respectively in the
Molecular Docking studies.
Molecular Docking simulations were carried out utiliz-
ing the Lamarckian genetic algorithm (LGA), and the
Solis & Wets local search method (Solis and Wets
1981). Initial position, orientation, and torsions of the
ligand molecules (Withaferin A and Bevacizumab) were
set on randomly basis. Each docking experiment was de-
rived from 10 different consecutive runs that were set to
terminate automatically after a maximum of 250000A B
Figure 2 Structural presentation of ligand molecules. (A) Withaferin A
naturally occurring C28- steroidal lactones. The basic structure of withanoli
lactone. (B) 2D structure of Withaferin A. (C) 2D structure of Bevacizumab.energy evaluations. The population size of the docking
was set to 150. During the search, a translational step of
0.2 Å, and quaternion and torsion steps of 5 were ap-
plied in the current docking.
Molecular docking using SwissDock
Molecular Docking calculations were performed using
SwissDock (http://swissdock.vital-it.ch/) web service
based on the docking software EADock DSS (Grosdidier
et al. 2011a). This web-based service was selected be-
cause it has user friendly interface with the facility to in-
put desired protein and ligand structures directly from
databases, modify docking parameters, and visualize
most favorable clusters online. Moreover, results can be
downloaded and viewed in UCSF Chimera package.
A grid (Box size: 40×40×40 Å and box center:
0.38×−2.98×20.51 for x,y, and z, respectively) wasC
falls under the family of compounds known as Withanolides, which are
de skeleton designated as a 22-hydroxyergostan-26-oicacid-26,22-

















Withaferin A −6.09 34.53 −7.59 −0.07 −7.66 10% 765.844
Bevacizumab −5.59 79.65 −5.97 −1.65 −7.62 20% 654.544
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for the most favorable bindings. Simultaneously, their
CHARMM energies are estimated on the grid (Grosdidier
et al. 2011b). Docking type was accurate and rigid. Each
docking experiment was derived from 250 different con-
secutive runs. The binding modes with the most favorable
energies were evaluated with Fast analytical continuum
treatment of solvation (FACTS), and clustered. Binding
modes were scored using their FullFitness and clustered.
Clusters were then ranked according to the average
FullFitness of their elements (Grosdidier et al. 2007). Re-
sults of the SwissDock were visualized by UCSF Chimera
package (Pettersen et al. 2004).Figure 3 Visualization of Withaferin A/Bevacizumab-VEGF protein inte
VEGF interaction by DockingServer. Representation of VEGF: cartoon, colou
colour: blue; representation of Withaferin A: ball and stick, carbon colour: g
DockingServer. Representation of VEGF: cartoon, colour: silver; representatio
representation of Bevacizumab: ball and stick, carbon colour: green. (C) Sur
Withaferin A is indicated as red surface and interacting side chain of VEGF
VEGF interaction by DockingServer. Bevacizumab is indicated as red surfaceResults and discussion
In the studies by DockingServer, the parameters of free
energy of binding, inhibition constant (Ki), total esti-
mated energy of vdW+Hbond+desolv(EVHD), electro-
static energy, total intermolecular energy, frequency of
binding, and interact surface area were evaluated to esti-
mate the favorable binding of ligand molecules to the
protein. Table 1 shows the complete profile of these pa-
rameters of both Withaferin A and Bevacizumab for
their interaction with VEGF. For the most favorable
binding of Withaferin A, estimated free energy of bind-
ing was of −6.09 kcal/mol, and total intermolecular en-
ergy was of −7.66 kcal/mol. In case of binding ofraction profile by DockingServer. (A) Visualization of Withaferin A-
r: silver; representation of interacting side chain: cylinder, carbon
reen. (B) Visualization of Bevacizumab-VEGF interaction by
n of interacting side chain: cylinder, carbon colour: blue;
face visualization of Withaferin A-VEGF interaction by DockingServer.
is indicated as blue surface. (D) Surface visualization of Bevacizumab-
and interacting side chain of VEGF is indicated as blue surface.
Figure 4 2D plot of Withaferin A/Bevacizumab-VEGF protein interaction profile by DockingServer. (A) 2D plot of Withaferin A-VEGF
interaction by DockingServer. Ligand bond, non-ligand bond, hydrogen bond and its length are mentioned. (B) 2D plot of Bevacizumab-VEGF
interaction by DockingServer. Ligand bond, non-ligand bond, hydrogen bond and its length are mentioned.
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−5.59 kcal/mol, and total intermolecular energy was of
−7.62 kcal/mol. In comparison to Bevacizumab,
Withaferin A exhibited comparatively low free energy of
interaction and intermolecular energy. Withaferin A
showed the inhibition constant (ki) of 34.53 uM, where-
as Bevacizumab showed Ki of 79.65 uM. Figure 3 shows
the binding of the legands to the protein. A 2D plot was
generated where ligand bond, non-ligand bond, and
hydrogen bonds along with their length were mentioned
(Figure 4). Decomposed interaction energies of hydrogen
bonds, polar, hydrophobic, and other bonds are men-
tioned in Table 2. Additional file 1 shows the interaction
profile of hydrogen bonds, polar, hydrophobic and others.
A HB plot (Bikadi et al. 2007, McDonald and ThorntonTable 2 Decomposed interaction energies in kcal/mol by Doc
Ligand Hydrogen bonds Polar bonds
Withaferin A Cys 61 (0) Thr 31 (−0.4238), Ser 50 (−
Glu 64 (0)
Bevacizumab Glu 64 (−1.0692); Asp 34 (0) ———1994) was generated to mention interactions with differ-
ent amino acids of the protein (Figure 5).
In the studies by SwissDock, FullFitness and Gibbs
free energy (ΔG) of each run (250 runs) of the docking
were evaluated. Favorable binding modes were scored
based on FullFitness and cluster formation. Ranking of
the cluster was performed using the value of FullFitness.
Tables 3 and 4 shows the clustering results obtained
from the docking of the ligands into VEGF protein.
Withaferin A showed FullFitness of −1948.69 kcal/mol
and estimated ΔG of −7.24 kcal/mol for the most favor-
able interaction, whereas Bevacizumab showed FullFitness
of −2221.84 kcal/mol and ΔG of −7.56 kcal/mol. Figure 6
shows the visualization of the most energetically favorable
binding of the legands into the protein VEGF.kingServer
Hydrophobic bonds Other bonds
0.1325), Cys 51 (−0.1675), Cys 60 (0) Leu 32 (−0.1934), Glu 67 (0),
Ile 29 (0), Lys 107 (0)
Phe 36 (0) Phe 47 (0); Ser 50 (0)
Figure 5 HB plot of Withaferin A/Bevacizumab-VEGF protein interaction profile by DockingServer. (A) HB plot structure of Withaferin
A-VEGF interaction by DockingServer. Interactions with amino acids: 29: Ile, 31: Thr, 32: Leu, 50: Ser, 51: Cys, 60: Cys, 61: Cys, 64: Glu, 67: Glu, and 107: Cys.
(B) HB Plot structure of Bevacizumab-VEGF interaction by DockingServer. Interactions with amino acids: 34: Asp, 36: Phe, 47: Phe, 50: Ser, and 64: Glu.
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clearly expressed that Withaferin A showed favorable
binding with VEGF, and the results were highly compar-
able with the commercially available drug Bevacizumab.
VEGF, as an angiogenic protein stimulates the process of
angiogenesis through chemical stimulation. Withaferin
A shows favorable binding with VEGF, which can be po-
tential way to prevent chemical stimulation of VEGF to
induce angiogenesis process in hypoxic condition of the
solid tumors. Moreover, VEGF is considered as one of
the most vital pro-angiogenic factors involved in tumor
angiogenesis (Moreira et al., 2007). VEGF increases vas-
cular permeability which propagates tumor dissemin-
ation with the supply of sufficient oxygen and nutrients
(Moreira et al., 2007). Inhibition of VEGF can prevent
aggressive tumor angiogenesis which prevents the supply
of oxygen and nutrients, necessary for propagation of
tumor; ultimate outcome is the retardation of tumor
growth.
In hypoxic condition, up-regulation of hypoxia indu-
cible factor (HIF1), provokes VEGF growth factor, which
in association with other cytokines, induces neovas-
cularization of tumors and creates favorable conditionsTable 3 Clustering results obtained from the docking of
Withaferin A into VEGF by SwissDock












5 −1944.75 −6.79to grow beyond the size limitation (Martinez et al.,
2003). For the first time, VEGF was accused in angiogen-
esis when it was identified as a growth factor secreted by
solid tumor cells, which caused the hyperpermeability of
normal blood vessels (Senger et al., 1983). Though VEGF
presents in almost every type of tumor, but it is high in
concentration in the tumor blood vessels and hypoxic
area of the tumor. VEGF binds with specific receptor, so
inhibition of VEGF receptor or inhibition of VEGF to
bind with the receptor can definitely retard the growth
of solid tumors (Millauer et al., 1996). It has already
been experimented that the injection of an antibody
VEGF, suppresses the growth of solid tumors of human
fibrosarcoma cell line HT-1080 (Asano et al., 1995).
Recently, in cancer therapy, new strategies show the
clinical relevance of inhibiting VEGF when the angio-
genesis process is exaggerated, particularly in patho-
logical angiogenesis (Olsson et al., 2006). However, such
therapies in the long term management of cancer can
hamper the survival of blood vessels in the healthy tis-
sues (Olsson et al., 2006). So, in the development of the
inhibitor of VEGF, it is vital to preserve the pathways as-
sociated with the survival of blood vessels necessary to
conduct normal physiological function and development
(Olsson et al., 2006). In addition, VEGF is essential for
transporting oxygen, nutrients, and the removal of car-
bon dioxide and metabolic end products from cells, tis-
sues, and organs to accomplish normal physiological
phenomena (Cines et al., 1998). In tumor therapy, while
using VEGF inhibitor, we have to calculate risk benefit
ratio to validate the therapy.
Throughout the study, Withaferin A was better VEGF
inhibitor than Bevacizumab in aspect of binding and af-
finity. Clinically, Bevacizumab is the most successful
Table 4 Clustering results obtained from the docking of
Bevacizumab into VEGF by SwissDock













Figure 6 Visualization of Withaferin A/Bevacizumab-VEGF protein inte
interaction by SwissDock. (B) Visualization of Bevacizumab-VEGF interaction
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United States Food and Drug Administration (FDA) in
the year of 2004 (Olsson et al., 2006). In combination
with chemotherapy, Bevacizumab prolongs the survival
rate of patients with solid tumor (Olsson et al., 2006). It
has been often regarded that anti-VEGF drugs normalize
the tumor blood vessels, which ensures more efficient de-
livery of the chemotherapy drugs in the tissue (Jain 2005).
In addition, another anti-VEGF drug, Ranibizumab, de-
rived from the same mouse antibody as Bevacizumab,
playing their role in controlling angiogenesis through the
inhibition of a number of subtypes of VEGF (Haberfeld
2009). Withaferin A showed more promising activity than
Bevacizumab in molecular docking studies which leadsraction profile by SwissDock. (A) Visualization of Withaferin A-VEGF
by SwissDock. Visualization is performed using UCSF Chimera.
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hibitor with lower side-effects because of its natural origin.
Though only VEGF inhibition can’t inhibit tumor angio-
genesis because there are many other endogenous anti-
angiogenic factors available in our physiological system,
but it can definitely retard aggressiveness of the tumor
angiogenesis in some extent (Roskoski 2007).
Conclusions
The protein-ligand interaction studies play a vital role in
the structure based drug design in dry lab. VEGF is one
of the most attractive topics in cancer biology, biochem-
istry, and pharmacology, and in the recent years the
number of studies focusing on its inhibition has increased
manifolds. Present study, has given a new insight to inhibit
VEGF with the key metabolite, Withaferin A of Withania
somnifera. Further investigations like QSAR studies are re-
quired to study semi-synthetic derivatives of Withaferin A
to get more favorable interaction into VEGF.
Additional file
Additional file 1: Table S1. (A) Withaferin A-VEGF Interaction profile
by DockingServer. (B) Bevacizumab-VEGF Interaction profile by
DockingServer.
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